Disease Associations
Lymphoma patients have delayed HBV reactivation after lamivudine cessation
Published in Hepatitis Weekly, January 10th, 2005
According to recent research published in the journal Annals of Hematology, "preemptive lamivudine in lymphoma patients undergoing intensive chemotherapy can effectively prevent chemotherapy-related HBV reactivation. Nevertheless, the safety profile after withdrawal of lamivudine and the impact of rituximab-containing chemotherapy on HBV reactivation has not been defined."
"To illustrate the necessity of prolonged surveillance after cessation of preemptive lamivudine in lymphoma patients treated with rituximab and chemotherapy, four patients with B-cell NHL carrying...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-01-10)
More Articles from Hepatitis Weekly
- Immunology
Low exposures to hepatitis C generate an immune response but not infection - Oncology
Liver transplantation benefits patients with early-stage liver cancer - Transfusion Medicine
New data support an indirect link between hepatitis C and thyroid cancer - Transplant Medicine
Hepatitis B viremia before liver transplantation guides post-surgical therapy - Addiction Medicine
Many hepatitis B virus-infected intravenous drug users carry mixed genotypes - Anesthesiology
Metabolic effects of propofol determined in isolated perfused rat liver - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
